SAEs with treatment discontinuation in the FCCam arm
| . | Events . | Occurrence . |
|---|---|---|
| Mucormycosis | 1 | After cycle 6 |
| Diffuse large B-cell lymphoma | 3 | After cycles 4 and 5 |
| EBV-associated lymphoproliferative disorder | 1 | After cycle 5 |
| Heart failure during neutropenia | 2 | After cycle 2 |
| Septic shock (Pseudomonas aeruginosa) | 1 | After end of evaluation |
| Gastrointestinal stromal tumor | 1 | After end of evaluation |
| Ocular toxoplasmosis | 1 | After cycle 6 |
| Pneumococcal sepsis | 1 | After cycle 1 |
| Pneumonia/Clostridium difficile colitis | 1 | After cycle 5 |
| Respiratory insufficiency | 1 | After end of evaluation |
| Subdural hematoma | 1 | After cycle 1 |
| Tumor lysis syndrome | 1 | After cycle 1 |
| . | Events . | Occurrence . |
|---|---|---|
| Mucormycosis | 1 | After cycle 6 |
| Diffuse large B-cell lymphoma | 3 | After cycles 4 and 5 |
| EBV-associated lymphoproliferative disorder | 1 | After cycle 5 |
| Heart failure during neutropenia | 2 | After cycle 2 |
| Septic shock (Pseudomonas aeruginosa) | 1 | After end of evaluation |
| Gastrointestinal stromal tumor | 1 | After end of evaluation |
| Ocular toxoplasmosis | 1 | After cycle 6 |
| Pneumococcal sepsis | 1 | After cycle 1 |
| Pneumonia/Clostridium difficile colitis | 1 | After cycle 5 |
| Respiratory insufficiency | 1 | After end of evaluation |
| Subdural hematoma | 1 | After cycle 1 |
| Tumor lysis syndrome | 1 | After cycle 1 |